Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Thousands |
|
3 Months Ended |
9 Months Ended |
Oct. 28, 2016 |
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
| Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] |
|
|
|
|
|
| Contingent cash amount to be paid as percent of payments received by Transcept on or before second anniversary |
|
|
|
100.00%
|
|
| Contingent cash amount to be paid as percent of payments received by Transcept for net sales criteria achievement |
|
|
|
100.00%
|
|
| Contingent cash amount to be paid as percent of cash proceeds from sale or disposition of Intermezzo |
|
|
|
90.00%
|
|
| Changes in fair value of contingent consideration |
|
$ (170)
|
$ (240)
|
$ (50)
|
$ (2,980)
|
| Contingent Obligations [Member] |
|
|
|
|
|
| Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] |
|
|
|
|
|
| Changes in fair value of contingent consideration |
|
|
|
$ (100)
|
|
| Subsequent Event [Member] | Transcept Pharmaceuticals, Inc. [Member] | Royalty Sharing Agreement [Member] |
|
|
|
|
|
| Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] |
|
|
|
|
|
| Percentage of royalty income paid for payment obligation |
50.00%
|
|
|
|
|